Open sidebar
Focus
biogen
Dementia & Alzheimer's
|
George Citroner
Controversial Alzheimer’s Drug Aduhelm Dropped by Drugmaker After Doubtful Data and Denied Coverage
The drug was discontinued by Biogen after inconsistent trial data, concerning side effects including brain swelling, and poor financial outlook.
Feb 01, 2024
|
George Citroner
Feb 01
|
US News
|
Frank Fang
Hundreds of Drugmakers Call for Reversal of Texas Court Ruling on Abortion Pill
Apr 11, 2023
|
Frank Fang
Apr 11
|
Health News
|
Katabella Roberts
VHA to Cover Eisai, Biogen’s Alzheimer’s Drug for Eligible Veterans
Mar 14, 2023
|
Katabella Roberts
Mar 14
|
Courts
|
Katabella Roberts
Biogen Agrees to Pay $900 Million in Drug Kickbacks Settlement, Denies Wrongdoing
Sep 27, 2022
|
Katabella Roberts
Sep 27
|
Medicine
|
Health 1+1
,
Kelly Song
FDA Finally Approved an Alzheimer’s Drug—But Everything Surrounding It Is Controversial
Aug 20, 2022
|
Health 1+1
Aug 20
|
Companies
|
Reuters
Biogen, Eisai Alzheimer’s Drug Lecanemab Gets ‘Fast Track’ Designation From FDA
Dec 24, 2021
|
Reuters
Dec 24
|
Health
|
Reuters
Biogen Halves Price of Alzheimer’s Drug to $28,200
Dec 20, 2021
|
Reuters
Dec 20
|
Health
|
Judith Graham
Doctors Weigh Prescribing Controversial Alzheimer’s Drug
Jul 21, 2021
|
Judith Graham
Jul 21
|
US News
|
Reuters
US Review of Biogen Alzheimer’s Drug Could Have Been Handled Differently: FDA Chief
Jul 15, 2021
|
Reuters
Jul 15
|
US News
|
Reuters
FDA Approves Biogen Alzheimer’s Drug
Jun 07, 2021
|
Reuters
Jun 07
|
AMERICA
|
Zachary Stieber
15 New Coronavirus Cases Linked to Biogen Conference in Boston
Mar 09, 2020
|
Zachary Stieber
Mar 09
|
Companies
|
Reuters
Biogen Scraps Alzheimer Drug Trials, Wiping $17 Billion Off Its Market Value
Mar 21, 2019
|
Reuters
Mar 21
|